213 related articles for article (PubMed ID: 35654881)
1. Transient expression of an adenine base editor corrects the Hutchinson-Gilford progeria syndrome mutation and improves the skin phenotype in mice.
Whisenant D; Lim K; Revêchon G; Yao H; Bergo MO; Machtel P; Kim JS; Eriksson M
Nat Commun; 2022 Jun; 13(1):3068. PubMed ID: 35654881
[TBL] [Abstract][Full Text] [Related]
2. In vivo base editing rescues Hutchinson-Gilford progeria syndrome in mice.
Koblan LW; Erdos MR; Wilson C; Cabral WA; Levy JM; Xiong ZM; Tavarez UL; Davison LM; Gete YG; Mao X; Newby GA; Doherty SP; Narisu N; Sheng Q; Krilow C; Lin CY; Gordon LB; Cao K; Collins FS; Brown JD; Liu DR
Nature; 2021 Jan; 589(7843):608-614. PubMed ID: 33408413
[TBL] [Abstract][Full Text] [Related]
3. Identification of mitochondrial dysfunction in Hutchinson-Gilford progeria syndrome through use of stable isotope labeling with amino acids in cell culture.
Rivera-Torres J; Acín-Perez R; Cabezas-Sánchez P; Osorio FG; Gonzalez-Gómez C; Megias D; Cámara C; López-Otín C; Enríquez JA; Luque-García JL; Andrés V
J Proteomics; 2013 Oct; 91():466-77. PubMed ID: 23969228
[TBL] [Abstract][Full Text] [Related]
4. Impaired LEF1 Activation Accelerates iPSC-Derived Keratinocytes Differentiation in Hutchinson-Gilford Progeria Syndrome.
Mao X; Xiong ZM; Xue H; Brown MA; Gete YG; Yu R; Sun L; Cao K
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628310
[TBL] [Abstract][Full Text] [Related]
5. Emerging candidate treatment strategies for Hutchinson-Gilford progeria syndrome.
Strandgren C; Revêchon G; Sola-Carvajal A; Eriksson M
Biochem Soc Trans; 2017 Dec; 45(6):1279-1293. PubMed ID: 29127216
[TBL] [Abstract][Full Text] [Related]
6. Cellular stress and AMPK activation as a common mechanism of action linking the effects of metformin and diverse compounds that alleviate accelerated aging defects in Hutchinson-Gilford progeria syndrome.
Finley J
Med Hypotheses; 2018 Sep; 118():151-162. PubMed ID: 30037605
[TBL] [Abstract][Full Text] [Related]
7. Vascular Smooth Muscle-Specific Progerin Expression Accelerates Atherosclerosis and Death in a Mouse Model of Hutchinson-Gilford Progeria Syndrome.
Hamczyk MR; Villa-Bellosta R; Gonzalo P; Andrés-Manzano MJ; Nogales P; Bentzon JF; López-Otín C; Andrés V
Circulation; 2018 Jul; 138(3):266-282. PubMed ID: 29490993
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular Progerin Suppression and Lamin A Restoration Rescue Hutchinson-Gilford Progeria Syndrome.
Sánchez-López A; Espinós-Estévez C; González-Gómez C; Gonzalo P; Andrés-Manzano MJ; Fanjul V; Riquelme-Borja R; Hamczyk MR; Macías Á; Del Campo L; Camafeita E; Vázquez J; Barkaway A; Rolas L; Nourshargh S; Dorado B; Benedicto I; Andrés V
Circulation; 2021 Nov; 144(22):1777-1794. PubMed ID: 34694158
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic involvement in Hutchinson-Gilford progeria syndrome: a mini-review.
Arancio W; Pizzolanti G; Genovese SI; Pitrone M; Giordano C
Gerontology; 2014; 60(3):197-203. PubMed ID: 24603298
[TBL] [Abstract][Full Text] [Related]
10. Generation of a Hutchinson-Gilford progeria syndrome monkey model by base editing.
Wang F; Zhang W; Yang Q; Kang Y; Fan Y; Wei J; Liu Z; Dai S; Li H; Li Z; Xu L; Chu C; Qu J; Si C; Ji W; Liu GH; Long C; Niu Y
Protein Cell; 2020 Nov; 11(11):809-824. PubMed ID: 32729022
[TBL] [Abstract][Full Text] [Related]
11. Hutchinson-Gilford Progeria Syndrome (Hgps) and Application of Gene Therapy Based Crispr/Cas Technology as A Promising Innovative Treatment Approach.
Rajeev M; Ratan C; Krishnan K; Vijayan M
Recent Pat Biotechnol; 2021; 15(4):266-285. PubMed ID: 34602042
[TBL] [Abstract][Full Text] [Related]
12. Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition.
Glynn MW; Glover TW
Hum Mol Genet; 2005 Oct; 14(20):2959-69. PubMed ID: 16126733
[TBL] [Abstract][Full Text] [Related]
13. Vitamin D receptor signaling improves Hutchinson-Gilford progeria syndrome cellular phenotypes.
Kreienkamp R; Croke M; Neumann MA; Bedia-Diaz G; Graziano S; Dusso A; Dorsett D; Carlberg C; Gonzalo S
Oncotarget; 2016 May; 7(21):30018-31. PubMed ID: 27145372
[TBL] [Abstract][Full Text] [Related]
14. Reversible phenotype in a mouse model of Hutchinson-Gilford progeria syndrome.
Sagelius H; Rosengardten Y; Schmidt E; Sonnabend C; Rozell B; Eriksson M
J Med Genet; 2008 Dec; 45(12):794-801. PubMed ID: 18708427
[TBL] [Abstract][Full Text] [Related]
15. Transgene silencing of the Hutchinson-Gilford progeria syndrome mutation results in a reversible bone phenotype, whereas resveratrol treatment does not show overall beneficial effects.
Strandgren C; Nasser HA; McKenna T; Koskela A; Tuukkanen J; Ohlsson C; Rozell B; Eriksson M
FASEB J; 2015 Aug; 29(8):3193-205. PubMed ID: 25877214
[TBL] [Abstract][Full Text] [Related]
16. Absence of progeria-like disease phenotypes in knock-in mice expressing a non-farnesylated version of progerin.
Yang SH; Chang SY; Ren S; Wang Y; Andres DA; Spielmann HP; Fong LG; Young SG
Hum Mol Genet; 2011 Feb; 20(3):436-44. PubMed ID: 21088111
[TBL] [Abstract][Full Text] [Related]
17. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome.
Capell BC; Erdos MR; Madigan JP; Fiordalisi JJ; Varga R; Conneely KN; Gordon LB; Der CJ; Cox AD; Collins FS
Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12879-84. PubMed ID: 16129833
[TBL] [Abstract][Full Text] [Related]
18. Targeted transgenic expression of the mutation causing Hutchinson-Gilford progeria syndrome leads to proliferative and degenerative epidermal disease.
Sagelius H; Rosengardten Y; Hanif M; Erdos MR; Rozell B; Collins FS; Eriksson M
J Cell Sci; 2008 Apr; 121(Pt 7):969-78. PubMed ID: 18334552
[TBL] [Abstract][Full Text] [Related]
19. Discordant gene expression signatures and related phenotypic differences in lamin A- and A/C-related Hutchinson-Gilford progeria syndrome (HGPS).
Plasilova M; Chattopadhyay C; Ghosh A; Wenzel F; Demougin P; Noppen C; Schaub N; Szinnai G; Terracciano L; Heinimann K
PLoS One; 2011; 6(6):e21433. PubMed ID: 21738662
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel mitigates structural alterations and cardiac conduction system defects in a mouse model of Hutchinson-Gilford progeria syndrome.
Macías Á; Díaz-Larrosa JJ; Blanco Y; Fanjul V; González-Gómez C; Gonzalo P; Andrés-Manzano MJ; da Rocha AM; Ponce-Balbuena D; Allan A; Filgueiras-Rama D; Jalife J; Andrés V
Cardiovasc Res; 2022 Jan; 118(2):503-516. PubMed ID: 33624748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
